Elevated antinuclear antibodies and unprovoked venous thromboembolism: a case-control study
Novelty in Biomedicine,
Vol. 13 No. 2 (2025),
19 April 2025
,
Page 100-104
https://doi.org/10.22037/nbm.v13i2.47063
Abstract
Background: Unprovoked venous thromboembolism (VTE) can occur without traditional risk factors, and its underlying causes remain poorly understood. This study investigates the potential role of elevated antinuclear antibody (ANA) titers as a biomarker for unprovoked VTE.
Materials and Methods: A case-control study was conducted with 189 patients diagnosed with unprovoked VTE, and 189 matched controls without VTE between 2019 and 2023. ANA titers were measured using enzyme-linked immunosorbent assay (ELISA), and the association between elevated ANA titers and unprovoked VTE was assessed.
Results: The study revealed a significant association between elevated ANA titers and unprovoked VTE. The case group had a higher proportion of patients with ANA titers >1:100 (14.3%) compared to controls (3.7%) (p<0.001). Laboratory analysis showed significantly higher white blood cell count (p<0.001), lower mean corpuscular volume (p=0.03), and higher creatinine levels (p<0.001) in the case group. No significant differences were observed in hemoglobin or platelet levels (p=0.07 and p=0.89, respectively).
Conclusion: Elevated ANA titers may serve as a useful biomarker for identifying patients at risk for unprovoked VTE. Clinicians should consider autoimmune disorders in the differential diagnosis for unprovoked VTE. Early detection of elevated ANA could lead to targeted interventions and improved patient outcomes by reducing VTE recurrence and managing underlying autoimmune conditions.
- Unprovoked venous thromboembolism
- Antinuclear antibodies
- Autoimmune disorders
- Systemic lupus erythematosus
- Antiphospholipid syndrome
- Thrombotic events
How to Cite
References
Anderson Jr FA, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107(23_suppl_1):I-9-I-16.
White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(23_suppl_1):I-4-I-8.
Heit JA. Epidemiology of venous thromboembolism. Nature Reviews Cardiology. 2015;12(8):464-74.
Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. Journal of thrombosis and thrombolysis. 2016;41:3-14.
Khan F, Tritschler T, Kahn SR, Rodger MA. Venous thromboembolism. The lancet. 2021;398(10294):64-77.
Ageno W, Farjat A, Haas S, Weitz JI, Goldhaber SZ, Turpie AG, et al. Provoked versus unprovoked venous thromboembolism: findings from GARFIELD‐VTE. Research and practice in thrombosis and haemostasis. 2021;5(2):326-41.
Mwansa H, Zghouzi M, Barnes GD. Unprovoked venous thromboembolism: the search for the cause. Medical Clinics. 2023;107(5):861-82.
Becattini C, Cimini LA. Provoked vs minimally provoked vs unprovoked VTE: does it matter? Hematology. 2023;2023(1):600-05.
Natorska J, Celińska-Löwenhoff M, Undas A. High prevalence of antinuclear antibodies in patients following venous thromboembolism. 2018.
Ricard L, Laurent C, Papo M, Deriaz S, Catano J, Alamowitch S, et al. Clinical and prognostic significance of antinuclear antibodies in primary antiphospholipid syndrome: a multicenter retrospective study. Joint Bone Spine. 2022;89(2):105297.
Hoffman I, Peene I, Meheus L, Huizinga T, Cebecauer L, Isenberg D, et al. Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Annals of the rheumatic diseases. 2004;63(9):1155-58.
Sawalha AH, Harley JB. Antinuclear autoantibodies in systemic lupus erythematosus. Current opinion in rheumatology. 2004;16(5):534-40.
Pisetsky DS, Lipsky PE. New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nature Reviews Rheumatology. 2020;16(10):565-79.
Xiao Y, Lin Y, Zhang Y, Wang J, Zeng Y. Factors associated with the antinuclear antibody (ANA) titer of systemic autoimmune rheumatic diseases in ANA-positive patients after treatment: a retrospective study. Clinical and Experimental Medicine. 2022:1-8.
Bazzan M, Vaccarino A, Marletto F. Systemic lupus erythematosus and thrombosis. Thrombosis journal. 2015;13:1-10.
Hinojosa-Azaola A, Romero-Diaz J, Vargas-Ruiz AG, Nuñez-Alvarez CA, Cicero-Casarrubias A, Ocampo-Torres MC, et al. Venous and arterial thrombotic events in systemic lupus erythematosus. The Journal of Rheumatology. 2016;43(3):576-86.
Pons-Estel GJ, Andreoli L, Scanzi F, Cervera R, Tincani A. The antiphospholipid syndrome in patients with systemic lupus erythematosus. Journal of autoimmunity. 2017;76:10-20.
de Groot PG, de Laat B. Mechanisms of thrombosis in systemic lupus erythematosus and antiphospholipid syndrome. Best Practice & Research Clinical Rheumatology. 2017;31(3):334-41.
Egner W. The use of laboratory tests in the diagnosis of SLE. Journal of clinical pathology. 2000;53(6):424-32.
Sinico RA, Bollini B, Sabadini E, Di Toma L, Radice A. The use of laboratory tests in diagnosis and monitoring of systemic lupus erythematosus. Journal of nephrology. 2002;15:S20-27.
Kurien B, Scofield R. Autoantibody determination in the diagnosis of systemic lupus erythematosus. Scandinavian journal of immunology. 2006;64(3):227-35.
Alba P, Bertolaccini ML, Khamashta MA. The use of laboratory methods in differential diagnosis and treatment of SLE and antiphospholipid syndrome. Expert Review of Clinical Immunology. 2007;3(4):613-22.
Cohen D, Berger SP, Steup-Beekman GM, Bloemenkamp KW, Bajema IM. Diagnosis and management of the antiphospholipid syndrome. Bmj. 2010;340.
- Abstract Viewed: 16 times
- pdf Downloaded: 10 times